Call Now to Speak with a Care Manager Speak with a Care Manager Now: 405-285-4191

Doctors Believe New Medication Could Be the Future for Alzheimer’s

By Melissa Hill, 9:00 am on

Aducanumab is a drug that Oklahoma home care agencies believe might revolutionize the treatment of Alzheimer’s disease. This medication has been recently used in experiments featuring individuals with early stages of this disease that affects memory and other cognitive functions. Aducanumab is particularly effective when it comes to reducing amyloid-beta proteins, which are hazardous proteins that accumulate in the brain. People with Alzheimer’s disease have abnormal levels of amyloid-beta proteins, though the reason why is not yet fully understood by the scientific community. By producing plaque in the brain, amyloid-beta interferes with proper memory functions.

Manufacturer Biogen is taking a lead role in the research and development of aducanumab, which is bringing hope to Alzheimer’s and dementia caregivers in Oklahoma. This American company specializes in innovative biotechnology and pharmaceutical solutions for the global marketplace. Biogen is excited about launching this powerful drug that can have a positive impact on people with Alzheimer’s disease. There aren’t any similar drugs that can produce the types of biological changes that aducanumab can generate. Nevertheless, Biogen still has a long way to go before its revolutionary drug becomes approved by the FDA and other similar entities that regulate the pharmacy industry in the United States.

The recent research on aducanumab was mentioned in the 12th International Conference on Alzheimer’s and Parkinson’s Diseases. Held in Nice, France, this annual conference focused on the latest treatment options for some of the most common neurological problems among elderly people. 

When aducanumab was introduced into clinical trials, it showed some measurable results. For example, this drug decreased the levels of amyloid-beta proteins in a large percentage of study participants. PET scans were used to thoroughly check the brains of individuals who took this medication during the experiments. Additionally, some participants received high scores on the Mini Mental State Examination, which is a standard test that’s commonly used to identify early phases of dementia.

While Biogen continues to test aducanumab, seniors can turn to Oklahoma Home Care Assistance for help managing Alzheimer’s at home. We are the leading provider of dementia and Alzheimer’s home care Oklahoma seniors can trust to promote mental and emotional wellbeing in the comfort of home. Call 405-285-4191 today to learn more about our unique care plans and how we can customize one to meet your loved one’s needs.